Transplant (Hematologic) Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
12993B Collection and Use of Mobilized Peripheral Blood Stem Cells from Patients with Hematologic Malignancies
15147A Collection of Research Blood and/or Marrow Samples in Donors Undergoing Bone Marrow, Stem Cell or Lymphocyte Collection.
Select
15953A Protocol for a research database for hematopoietic Stem Cell Transplanation and Marrow Toxic Injuries _ REPLACES 13239B
15961A Protocol for a Research Sample Repository For Allogeneic Hematopioetic Stem Cell Transplanation_ REPLACES 12590A
10-064-B Molecular characterization of hematopoietic malignancies
11-0118 KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Select
12-0064 COG ANBL09P1: A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG/Irinotecan/Vincristine
Select
IRB12-1191 Pilot study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies
Select
IRB12-1924 A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)
12-1856 The University of Chicago Transplant Immunology and Immunogenetics Laboratory Research Registry and Specimen Collection Protocol for Biomedical Research
Select
IRB14-0085 A Phase II, Randomized Trial of Standard of Care, With or Without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
IRB13-1280 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Select
IRB14-0709 A Phase I Study Of Intensity Modulated Total Marrow Irradiation (IMTMI) In Addition To Fludarabine/Melphelan Conditioning For Allogeneic Transplantation For Advanced Hematologic Malignancies
IRB14-0816 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK8228-001)
IRB14-0205 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK8228-001)
Select
IRB14-1106 A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract (GS-US-218-0108)
Select
IRB14-1109 A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract (GS-US-218-1502)
IRB15-0536 Novel Prognostication in Hematopoietic Cell Transplantation (HCT).

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team